ClinicalTrials.gg
CompletedNCT01226043Pen PreferenceUpdated Aug 12, 2013Results posted

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-08-12.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
55th of 175
405 · median 253
Started
2010
with 12 others
Phase 4
103 of 176
2 open now
Registered
86th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 55th largest by enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2010, is one of 103 in phase 4, and was the 86th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM)

Secondary Objectives:

To compare Lantus SoloSTAR pen versus Lantus vial and syringe with regard to the following parameters:

Randomization/Crossover phase:

  • Healthcare professional's (HCP) recommendation for Lantus SoloSTAR pen versus Lantus vial and syringe

Re-randomization phase:

  • Change in Fasting Plasma Glucose (FPG) from week 4 to week 10
  • Percentage of patients achieving FPG\<110 mg/dL at week 10
  • Change in Lantus dose injected per day (U) from week 4 to week 10

Observational phase:

  • Percentage of patients achieving glycosylated hemoglobin (HbA1c) goal (\<7%) at week 40
  • Time to first observation of HbA1c\<7% during the observational phase
  • Percentage of patients who discontinue Investigational Product (IP) during the observational phase due to dissatisfaction with their current device

All phases:

  • Percentage of patients who discontinue IP during each phase of the study
  • Safety assessment such as occurrence of hypoglycemic events (HE) and adverse events (AE)
Read the detailed description

This study consisted of a 1 week Screening Phase, a 4-week Randomization/Crossover Phase, a 6-week Re-randomization Phase, followed by a 30 week Observational Phase.

The total duration of study participation was up to 41 weeks with a total treatment duration of up to 40 weeks of Lantus exposure.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with a confirmed diagnosis of type 2 diabetes mellitus who were treated with any combination of 2 or 3 oral antidiabetic drugs (OADs) at a stable dose for the preceding 3 months, including but not limited to:

  • Metformin + sulfonylurea + thiazolidinedione (Pioglitazone)
  • Metformin + sulfonylurea
  • Metformin + thiazolidinedione (Pioglitazone)
  • Metformin + dipeptidyl peptidase (DPPIV)

And for whom the Investigator/treating physician had decided that basal insulin was appropriate.

Patients who had signed an Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form

Exclusion criteria

Exclusion criteria:

  • Patients less than 18 years or greater than 85 years of age (ie, have not reached the age of 86 at the screening visit)
  • Patients with a confirmed diagnosis of type 1 diabetes mellitus
  • Patients who were treated with insulin or who had been treated with insulin in the preceding 12 months with the exception of insulin treatment during hospitalization (ie, patients who received insulin while hospitalized could be included)
  • Patients whose screening is \<7% or >10%
  • Patients with current addiction or current alcohol / drug abuse
  • Patients with cardiac status III-IV
  • Patients with stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or unstable angina pectoris within the 12 months prior to screening
  • Patients with a diagnosis of dementia, severe visual or dexterity impairment
  • Patients with any within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in situ
  • Patients with concomitant disease or concomitant medication that could interfere with treatment or ability to answer questionnaires
  • Patients who were unable to self-inject
  • Patients who were taking or had been treated with Byetta® (exenatide) or other Glucagon-Like Peptide-1 agonists within 3 months before screening:
  • Patients who were pregnant or breastfeeding
  • Women of not protected by a highly effective method of birth control (as defined for contraception in the Form and /or in a local protocol addendum) and/or who were unwilling or unable to be tested for pregnancy
  • Patients with impaired renal function as shown by serum creatinine ≥1.5 mg/dL for males or ≥1.4 mg/dL for females at screening
  • Patients with clinical evidence of active liver disease, or serum (ALT) or aspartate aminotransferase (AST) 2.5 times the (ULN)
  • Patients unlikely to comply with the protocol requirements (eg, illiterate, uncooperative, unable to return for scheduled visits, unlikely to complete the study)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Lantus (insulin glargine) vial & syringe

    10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.

    Drug: Insulin Glargine

  • Experimental
    Lantus (insulin glargine) SoloSTAR pen

    3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.

    Drug: Insulin Glargine

Interventions

  • * Pharmaceutical form: solution for injection * Route of administration: subcutaneous

    Also known as: Lantus

06

What researchers measure

Primary outcomes

  1. Patient Overall Preference

    The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d "Overall, what is your level of preference for each of the insulin delivery systems?" 5 points scale: from 1=Not preferred to 5= Always preferred

    Time frame: At week 4 (end of crossover phase)

Secondary outcomes

  1. Patient Preference Composite Score

    The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire: * Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar? * Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin? * Question 14c: How strongly would you prefer each insulin delivery system for long-term use? Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.

    Time frame: At week 4 (end of crossover phase)

  2. Healthcare Professional's (HCP) Recommendation

    The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: "Overall, how strongly would you recommend each of the insulin delivery systems for your patients?" 5 points scale: from 1= Not Recommended to 5= Recommended

    Time frame: At week 4 (end of crossover phase)

  3. Change in Fasting Plasma Glucose (FPG)

    Time frame: From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)

  4. Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL

    Time frame: At week 10 (end of re-randomization phase)

  5. Change in Lantus Dose Injected Per Day

    Time frame: From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)

  6. Percentage of Patients Achieving HbA1c Goal

    Percentage of patients achieving HbA1c \< 7% at Week 40 (end of the observational phase)

    Time frame: measured at week 40 or at study discontinuation

  7. Time to First Observation of HbA1c <7%

    Time frame: From week 10 to week 40 (observational phase)

  8. Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase

    Time frame: From baseline to week 4 (crossover phase)

  9. Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase

    Time frame: From week 4 to week 10 (re-randomization phase)

  10. Percentage of Patients Who Discontinued Investigational Product During the Observational Phase

    Time frame: From week 10 to week 40 (observational phase)

Other outcomes

  1. Number of Patients With Hypoglycemic Events

    The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) \<70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG \<36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG \>70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).

    Time frame: each study phase (crossover, re-randomization, observational) up to 40 weeks

07

Results

Posted Jul 30, 2013

Participant flow

Enrollment of patients started on October 26, 2010 and the study was completed on May 7, 2012. Patients were screened in 60 centers in the United States of America, of which 59 centers randomized patients.

4-week Crossover Phase - Period 1
Participant flow — 4-week Crossover Phase - Period 1
MilestonePen (Period 1) / Vial & Syringe (Period 2)Vial &Syringe (Period 1) / Pen (Period 2)SoloSTAR® PenVial and Syringe
Started20220300
Treated20220000
Completed19919400
Not completed3900
Withdrew: Protocol violation1200
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject2000
Withdrew: Physician decision0600
4-week Crossover Phase - Period 2
Participant flow — 4-week Crossover Phase - Period 2
MilestonePen (Period 1) / Vial & Syringe (Period 2)Vial &Syringe (Period 1) / Pen (Period 2)SoloSTAR® PenVial and Syringe
Started19919400
Treated19919400
Completed19518800
Not completed4600
Withdrew: Withdrawal by subject0100
Withdrew: Physician decision4500
6-week Re-randomization Phase
Participant flow — 6-week Re-randomization Phase
MilestonePen (Period 1) / Vial & Syringe (Period 2)Vial &Syringe (Period 1) / Pen (Period 2)SoloSTAR® PenVial and Syringe
Started00166167
Treated00165165
Completed00159156
Not completed00711
Withdrew: Adverse event0011
Withdrew: Protocol violation0011
Withdrew: Lost to follow-up0013
Withdrew: Withdrawal by subject0013
Withdrew: Physician decision0032
Withdrew: Completed in error0001
30-week Observational Phase
Participant flow — 30-week Observational Phase
MilestonePen (Period 1) / Vial & Syringe (Period 2)Vial &Syringe (Period 1) / Pen (Period 2)SoloSTAR® PenVial and Syringe
Started00159153
Treated00159153
Completed00153140
Not completed00613
Withdrew: Adverse event0011
Withdrew: Protocol violation0001
Withdrew: Lost to follow-up0022
Withdrew: Withdrawal by subject0017
Withdrew: Physician decision0022

Outcome measures

PrimaryPatient Overall Preference

The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d "Overall, what is your level of preference for each of the insulin delivery systems?" 5 points scale: from 1=Not preferred to 5= Always preferred

Time frame:
At week 4 (end of crossover phase)
Reported as:
Least squares mean · units on a scale
Patient Overall Preference
units on a scaleSoloSTAR® PenVial and Syringe
Patient Overall Preference4.75 ± 4.752.45 (2.35 to 2.56)
Statistical analysis
  • SoloSTAR® Pen vs Vial and Syringe · ANOVA · p = <0.0001 · Mean difference (net): 2.3 · 95% CI 2.15 to 2.44The last observation carried forward (LOCF) method was applied to impute missing Week 4 overall patient preference values for ANOVA analysis.
SecondaryPatient Preference Composite Score

The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire: * Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar? * Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin? * Question 14c: How strongly would you prefer each insulin delivery system for long-term use? Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.

Time frame:
At week 4 (end of crossover phase)
Reported as:
Least squares mean · units on a scale
Patient Preference Composite Score
units on a scaleSoloSTAR® PenVial and Syringe
Patient Preference Composite Score14.2 (13.88 to 14.44)7.49 (7.21 to 7.77)
SecondaryHealthcare Professional's (HCP) Recommendation

The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: "Overall, how strongly would you recommend each of the insulin delivery systems for your patients?" 5 points scale: from 1= Not Recommended to 5= Recommended

Time frame:
At week 4 (end of crossover phase)
Reported as:
Median · units on a scale
Healthcare Professional's (HCP) Recommendation
units on a scaleSoloSTAR® PenVial and Syringe
Healthcare Professional's (HCP) Recommendation5.0 (4 to 5)3.0 (1 to 5)
SecondaryChange in Fasting Plasma Glucose (FPG)
Time frame:
From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose (FPG)
mg/dLSoloSTAR® PenVial and Syringe
Change in Fasting Plasma Glucose (FPG)-14.3 ± 2.87-14.5 ± 2.91
SecondaryPercentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL
Time frame:
At week 10 (end of re-randomization phase)
Reported as:
Number · percentage of patients
Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL
percentage of patientsSoloSTAR® PenVial and Syringe
Percentage of Patients Achieving Fasting Plasma Glucose (FPG) <110 mg/dL28.830.5
SecondaryChange in Lantus Dose Injected Per Day
Time frame:
From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)
Reported as:
Least squares mean · U (insulin unit)
Change in Lantus Dose Injected Per Day
U (insulin unit)SoloSTAR® PenVial and Syringe
Change in Lantus Dose Injected Per Day6.361 ± 0.7866.336 ± 0.796
SecondaryPercentage of Patients Achieving HbA1c Goal

Percentage of patients achieving HbA1c \< 7% at Week 40 (end of the observational phase)

Time frame:
measured at week 40 or at study discontinuation
Reported as:
Number · percentage of patients
Percentage of Patients Achieving HbA1c Goal
percentage of patientsSoloSTAR® PenVial and Syringe
Percentage of Patients Achieving HbA1c Goal37.737.0
SecondaryTime to First Observation of HbA1c <7%
Time frame:
From week 10 to week 40 (observational phase)
Reported as:
Median · Days since Re-randomization (week 4)
Time to First Observation of HbA1c <7%
Days since Re-randomization (week 4)SoloSTAR® PenVial and Syringe
Time to First Observation of HbA1c <7%166 (88 to 248)168 (91 to 250)
SecondaryPercentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase
Time frame:
From baseline to week 4 (crossover phase)
Reported as:
Number · percentage of patients
Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase
percentage of patientsSoloSTAR® Pen (Period 1)Vial and Syringe (Period 2)SoloSTAR® Pen (Period 2)Vial and Syringe (Period 1)
Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase1.492.013.093.00
SecondaryPercentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase
Time frame:
From week 4 to week 10 (re-randomization phase)
Reported as:
Number · percentage of patients
Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase
percentage of patientsSoloSTAR® PenVial and Syringe
Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase3.65.5
SecondaryPercentage of Patients Who Discontinued Investigational Product During the Observational Phase
Time frame:
From week 10 to week 40 (observational phase)
Reported as:
Number · percentage of patients
Percentage of Patients Who Discontinued Investigational Product During the Observational Phase
percentage of patientsSoloSTAR® PenVial and Syringe
Percentage of Patients Who Discontinued Investigational Product During the Observational Phase3.88.5
Other pre-specifiedNumber of Patients With Hypoglycemic Events

The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) \<70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG \<36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG \>70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).

Time frame:
each study phase (crossover, re-randomization, observational) up to 40 weeks
Reported as:
Number · participants having reported the event
Number of Patients With Hypoglycemic Events
participants having reported the eventCrossover Phase: SoloSTAR® PenCrossover Phase: Vial and SyringeRe-randomization Phase: SoloSTAR® PenRe-randomization Phase: Vial and SyringeObservational Phase: SoloSTAR® PenObservational Phase: Vial and Syringe
Hypoglycemic event with or without SMBG728343487673
Hypoglycemia with SMBG698138477571
Symptomatic hypoglycemia576837376161
Hypoglycemia, assistance required3225811
Severe hypoglycemia3224711
Serious hypoglycemia000000

Adverse events

Collected over The median of exposure to each device was 14 days during the crossover phase. The median of exposure was 43 days in both arms during the re-randomization phase. During the observational phase, it was 209 days in the pen arm and 210 days in the vial arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crossover Phase: SoloSTAR® Pen—4/396 (1%)18/396 (4.5%)
Crossover Phase: Vial and Syringe—1/399 (0.3%)5/399 (1.3%)
Re-randomization Phase: SoloSTAR® Pen—1/165 (0.6%)12/165 (7.3%)
Re-randomization Phase: Vial and Syringe—0/165 (0%)14/165 (8.5%)
Observational Phase: SoloSTAR® Pen—16/159 (10.1%)35/159 (22%)
Observational Phase: Vial and Syringe—14/153 (9.2%)34/153 (22.2%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventCrossover Phase: SoloSTAR® PenCrossover Phase: Vial and SyringeRe-randomization Phase: SoloSTAR® PenRe-randomization Phase: Vial and SyringeObservational Phase: SoloSTAR® PenObservational Phase: Vial and Syringe
Non-cardiac chest painNervous system disorders0/3960/3990/1650/1651/1592/153
Atrial fibrillationCardiac disorders0/3960/3990/1650/1652/1591/153
Angina unstableCardiac disorders0/3960/3990/1650/1650/1591/153
ArthralgiaMusculoskeletal and connective tissue disorders0/3960/3990/1650/1650/1591/153
Bipolar I disorderPsychiatric disorders0/3960/3990/1650/1650/1591/153
Breast calcificationsReproductive system and breast disorders0/3960/3990/1650/1650/1591/153
Cerebrovascular accidentCardiac disorders0/3960/3990/1650/1650/1591/153
Chest painCardiac disorders0/3960/3990/1650/1650/1591/153
DiarrhoeaCardiac disorders0/3960/3990/1650/1650/1591/153
Duodenal ulcer haemorrhageCardiac disorders0/3960/3990/1650/1650/1591/153
Most frequent other events
Most frequent other events
EventCrossover Phase: SoloSTAR® PenCrossover Phase: Vial and SyringeRe-randomization Phase: SoloSTAR® PenRe-randomization Phase: Vial and SyringeObservational Phase: SoloSTAR® PenObservational Phase: Vial and Syringe
Upper respiratory tract infectionInfections and infestations7/3962/3994/1651/16514/15912/153
NasopharyngitisInfections and infestations5/3960/3996/1654/1657/15913/153
SinusitisInfections and infestations4/3961/3992/1656/16512/1596/153
Oedema peripheralGeneral disorders2/3962/3990/1653/1658/1593/153

Baseline characteristics

Baseline characteristics provided for the population randomized for the first phase of the study: crossover phase.

Age, Categorical
Age, Categorical(Participants)Crossover Phase: Pen / Vial & SyringeCrossover Phase: Vial & Syringe / PenTotal
<=18 years000
Between 18 and 65 years153146299
>=65 years4957106
Age Continuous
Age Continuous(years)Crossover Phase: Pen / Vial & SyringeCrossover Phase: Vial & Syringe / PenTotal
Mean57.7 ± 10.158.1 ± 10.957.9 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Crossover Phase: Pen / Vial & SyringeCrossover Phase: Vial & Syringe / PenTotal
Female10088188
Male102115217
Body Weight
Body Weight(kg)Crossover Phase: Pen / Vial & SyringeCrossover Phase: Vial & Syringe / PenTotal
Mean103.80 ± 26.4398.48 ± 20.75101.13 ± 23.87
Body Mass Index
Body Mass Index(kg/m^2)Crossover Phase: Pen / Vial & SyringeCrossover Phase: Vial & Syringe / PenTotal
Mean35.93 ± 7.8733.73 ± 6.6434.83 ± 7.35
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2010
First posted
Oct 21, 2010
Start
Oct 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jul 30, 2013
Last update
Aug 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01226043
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 21, 2010
Start date
Oct 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Jul 30, 2013
Last update
Aug 12, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion